Biopharmaceutical companies continued to aggressively pursue initial public offerings in the US during 2019 and in the end these firms gave IPO investors an average return of 45.1% as of 2 January. Conversely, 67 drug developers went public in 2018 and by the start of 2019 they had provided a -7.5% loss.
The IPO class of 2019 underwent a remarkable turnaround late in the year, since the average return for the 35...






